CXCR2 and chronic obstructive pulmonary disease: A 6-month trial assessed the CXCR2 antagonist MK-7123 in moderate-to-severe COPD patients and found that it significantly improved FEV1 (mean difference: 67 mL) and reduced sputum neutrophil counts [17].